• Profile

Treatment continuation of asenapine or olanzapine in Japanese schizophrenia patients: A propensity score matched study

Neuropsychiatric Disease and Treatment Dec 16, 2021

Matsuzaki H, Hatano M, Iwata M, et al. - Asenapine, a second-generation antipsychotic agent, is classified as a multi-acting receptor-targeted antipsychotic and is identified as similar to olanzapine. Researchers aimed to compare the treatment continuation rate and reason for discontinuation of asenapine vs olanzapine in schizophrenia using real-world data.

  • A retrospective study including 95 patients (asenapine, n = 46; olanzapine, n = 49).

  • The asenapine group and the olanzapine group had the continuation rates of 27.3% and 50.8%, respectively, at 6 months.

  • Because of the lack of efficacy, discontinuation rate for asenapine (13.0%) and olanzapine (10.2%) were almost similar.

  • Only asenapine group had discontinuations due to bitter taste (6.5%) and burden of the dosing method (6.5%), whereas only olanzapine had anticholinergic side effects such as dry mouth (4.1%) and constipation (2.0%).

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen